2023 World Conference on Lung Cancer (Posters)-EP13.01. Does Oligometastases state exist in patients of Small Cell Lung Cancer? - A Small Retrospective Analysis from a Tertiary Cancer Centre

EP13.01. Does Oligometastases state exist in patients of Small Cell Lung Cancer? - A Small Retrospective Analysis from a Tertiary Cancer Centre - PDF(Slides)

Back to course

Pdf Summary

This study aimed to assess the existence of oligometastases (OM) in patients with Small Cell Lung Cancer (SCLC) and evaluate the survival outcomes in this population. A total of 21 SCLC patients with 1-3 metastatic sites were included in the retrospective analysis. All patients received palliative platinum doublet chemotherapy, and radiation therapy was delivered to the primary and metastatic sites as feasible.<br /><br />The median follow-up was 9 months, and the median progression-free survival (PFS) and overall survival (OS) were 8 months and 14 months, respectively. At 1 year, 70% of patients were still alive. Fifteen patients received thoracic radiation therapy, with eight receiving definitive treatment and seven receiving consolidation therapy.<br /><br />The study found that limited metastatic OM in SCLC could potentially result in better survival outcomes compared to existing literature. The authors suggest that intensifying local therapy with immunotherapy may further improve survival outcomes. OM SCLC was found to be present in a small proportion of patients with atypical presentations such as females, non-smokers, and minimal nodal disease burden. However, larger studies are needed to confirm these findings.<br /><br />Among the findings, radiation therapy to the primary site was identified as a significant prognostic factor for overall survival. Additionally, seven patients developed progressive disease, with five of them experiencing progression at pre-existing OM sites.<br /><br />In conclusion, this study provides evidence that limited metastatic OM SCLC may have better survival outcomes in a carefully selected cohort. The authors suggest that further research is necessary, with larger studies and the inclusion of immunotherapy, to validate these findings and potentially improve treatment strategies for SCLC patients with oligometastases.

Asset Subtitle

Renu Nabariya

Meta Tag

Speaker Renu Nabariya

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

oligometastases

Small Cell Lung Cancer

SCLC

survival outcomes

palliative chemotherapy

radiation therapy

progression-free survival

overall survival

thoracic radiation therapy

prognostic factor